BARBARA ANN KARMANOS CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1995-01-01

Employees: 5K

Market Cap: -

Website: http://www.karmanos.org

Clinical Trials

Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Drug: carboplatin
Drug: paclitaxel
Drug: Zactima
Procedure: neoadjuvant therapy

First Posted Date: 2007-04-11

Last Posted Date: 2019-03-26

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 2

Registration Number: NCT00459121

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer

Interventions: Biological: bevacizumab
Drug: gemcitabine hydrochloride
Drug: pemetrexed disodium

First Posted Date: 2007-02-22

Last Posted Date: 2021-04-13

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 39

Registration Number: NCT00438204

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

Conditions: Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Precancerous Condition
Secondary Myelofibrosis

First Posted Date: 2007-01-18

Last Posted Date: 2016-02-29

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Registration Number: NCT00423826

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase 2

Completed

Conditions: Pancreatic Cancer

Interventions: Dietary Supplement: genistein
Drug: erlotinib hydrochloride
Drug: gemcitabine hydrochloride

First Posted Date: 2006-09-15

Last Posted Date: 2021-03-01

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00376948

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States

Skin Biopsies and DNA Analysis in Patients Receiving Irinotecan or Gemcitabine For Advanced Solid Tumors

Completed

Conditions: Breast Cancer
Pancreatic Cancer
Colorectal Cancer

First Posted Date: 2006-08-29

Last Posted Date: 2013-04-08

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 60

Registration Number: NCT00369109

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom

Diindolylmethane in Treating Patients With Nonmetastatic Prostate Cancer That Has Not Responded To Previous Hormone Therapy

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: BR-DIM

First Posted Date: 2006-03-22

Last Posted Date: 2014-01-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 12

Registration Number: NCT00305747

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Weisberg Cancer Treatment Center, Detroit, Michigan, United States

Cryotherapy in Treating Patients With Primary Lung Cancer or Lung Metastases That Cannot Be Removed By Surgery

Not Applicable

Completed

Conditions: Lung Cancer
Metastatic Cancer

Interventions: Procedure: cryosurgery
Procedure: positron emission tomography

First Posted Date: 2006-03-17

Last Posted Date: 2020-07-22

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00303901

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Cisplatin
Drug: Docetaxel
Drug: Pemetrexed disodium
Radiation: Radiation therapy

First Posted Date: 2006-03-13

Last Posted Date: 2023-05-06

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00301808

Locations: 🇺🇸
Veterans Affairs Medical Center - Detroit, Detroit, Michigan, United States
🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

Not Applicable

Completed

Conditions: Breast Cancer
Leukemia
Lymphoma
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasms
Nausea and Vomiting
Neuroblastoma
Ovarian Cancer
Testicular Germ Cell Tumor

Interventions: Drug: Aprepitant
Drug: Cyclophosphamide
Drug: Dexamethasone
Drug: Granisetron hydrochloride

First Posted Date: 2006-02-17

Last Posted Date: 2016-03-15

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 40

Registration Number: NCT00293384

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

Phase 1

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

Interventions: Drug: bortezomib

First Posted Date: 2006-02-07

Last Posted Date: 2013-11-19

Lead Sponsor: Barbara Ann Karmanos Cancer Institute

Target Recruit Count: 15

Registration Number: NCT00288028

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy